AR-V7-Driven Mitochondrial Metabolic Reprogramming in Enzalutamide-Resistant Prostate Cancer: Mechanisms and Therapeutic Implications
Enzalutamide resistance in castration-resistant prostate cancer (CRPC) is frequently driven by androgen receptor splice variant 7 (AR-V7), a prognostic biomarker that lacks the ligand-binding domain and evades enzalutamide inhibition; however, the downstream metabolic networks sustaining resistant-cell survival remain...